Therapeutic and Preventive Implications of Moonshot in Hereditary Cancer Syndromes Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Thursday, September 08, 2016

Therapeutic and Preventive Implications of Moonshot in Hereditary Cancer Syndromes



JAMA Oncology 
 

Full content is available to subscribers

Subscribe/Learn More
Viewpoint |

Osama Diab, MD1; Lakshmi Manogna Chintalacheruvu, MBBS1; Henry T. Lynch, MD2
JAMA Oncol. Published online September 08, 2016. doi:10.1001/jamaoncol.2016.3046

This Viewpoint discusses the significance of investing billions of dollars in genomic sequencing and the implications of finding a hereditary mutation in patients with metastatic cancer using next-generation sequencing.
An announcement was made regarding the initiation of a “moonshot” approach to the multifaceted cancer problems with the intent on reducing cancer mortality in the United States by accelerating cancer research to discover more therapies and focusing on finding new ways to prevent cancer and detect it in an early stage before it spreads. President Obama’s proposed fiscal year 2017 budget includes $1 billion for eliminating cancer. This initiative has led to the belief that concentrating on treatment is a limited approach to the overall reduction of cancer mortality, considering the success of cancer research in prevention.1 However, a powerful method for cancer prevention and survival has been the discipline of hereditary cancer syndromes. In this article, we discuss the significance of investing billions of dollars in genomic sequencing and the implications of finding a hereditary mutation in patients with metastatic cancer using next-generation sequencing (NGS).

0 comments :

Post a Comment

Your comments?